These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24187408)

  • 1. Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials.
    Gilbert PB; Shepherd BE; Hudgens MG
    J Am Stat Assoc; 2013 Jan; 108(503):. PubMed ID: 24187408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
    Gilbert PB; Bosch RJ; Hudgens MG
    Biometrics; 2003 Sep; 59(3):531-41. PubMed ID: 14601754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity Analyses Comparing Time-to-Event Outcomes Existing Only in a Subset Selected Postrandomization.
    Shepherd BE; Gilbert PB; Lumley T
    J Am Stat Assoc; 2007 Jun; 102(478):573-82. PubMed ID: 19122791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Causal inference for vaccine effects on infectiousness.
    Halloran ME; Hudgens MG
    Int J Biostat; 2012 Jan; 8(2):. PubMed ID: 22499732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating Causal Effects of Treatment in a Randomized Trial When Some Participants Only Partially Adhere.
    Shrier I; Platt RW; Steele RJ; Schnitzer M
    Epidemiology; 2018 Jan; 29(1):78-86. PubMed ID: 29023241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonparametric Bounds and Sensitivity Analysis of Treatment Effects.
    Richardson A; Hudgens MG; Gilbert PB; Fine JP
    Stat Sci; 2014 Nov; 29(4):596-618. PubMed ID: 25663743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of causal effects in clinical endpoint bioequivalence studies in the presence of intercurrent events: noncompliance and missing data.
    Lou Y; Jones MP; Sun W
    J Biopharm Stat; 2019; 29(1):151-173. PubMed ID: 29995564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simple Estimation of Patient-Oriented Effects From Randomized Trials: An Open and Shut CACE.
    Steele RJ; Shrier I; Kaufman JS; Platt RW
    Am J Epidemiol; 2015 Sep; 182(6):557-66. PubMed ID: 26283090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond.
    Rufibach K
    Pharm Stat; 2019 Mar; 18(2):145-165. PubMed ID: 30478869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Wang Y; Parker CE; Bhanji T; Feagan BG; MacDonald JK
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD000543. PubMed ID: 27101467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
    Feagan BG; Macdonald JK
    Cochrane Database Syst Rev; 2012 Oct; 10():CD000543. PubMed ID: 23076889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Centered Hazard Ratio Estimation Using Principal Stratification Weights: Application to the NORCCAP Randomized Trial of Colorectal Cancer Screening.
    MacKenzie TA; Løberg M; O'Malley AJ
    Obs Stud; 2016 Mar; 2():29-50. PubMed ID: 29644344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sharpening bounds on principal effects with covariates.
    Long DM; Hudgens MG
    Biometrics; 2013 Dec; 69(4):812-9. PubMed ID: 24245800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary on "Principal stratification - a goal or a tool?" by Judea Pearl.
    Gilbert PB; Hudgens MG; Wolfson J
    Int J Biostat; 2011; 7(1):Article 36. PubMed ID: 22049267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SENSITIVITY ANALYSIS FOR EVALUATING PRINCIPAL SURROGATE ENDPOINTS RELAXING THE EQUAL EARLY CLINICAL RISK ASSUMPTION.
    Huang Y; Zhuang Y; Gilbert P
    Ann Appl Stat; 2022 Sep; 16(3):1774-1794. PubMed ID: 37008748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surrogate Endpoint Evaluation: Principal Stratification Criteria and the Prentice Definition.
    Gilbert PB; Gabriel EE; Huang Y; Chan IS
    J Causal Inference; 2015 Sep; 3(2):157-175. PubMed ID: 26722639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(18):1-88. PubMed ID: 23074395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partially hidden Markov model for time-varying principal stratification in HIV prevention trials.
    Dai JY; Gilbert PB; Mâsse BR
    J Am Stat Assoc; 2012 Mar; 107(497):52-65. PubMed ID: 23667279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond intention to treat: what is the right question?
    Shrier I; Steele RJ; Verhagen E; Herbert R; Riddell CA; Kaufman JS
    Clin Trials; 2014 Feb; 11(1):28-37. PubMed ID: 24096636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.